Autoimmune Pancreatitis
Autoimmune pancreatitis (AIP) is an uncommon and intricate autoimmune disorder that impacts the pancreas. Our esteemed organization holds a prominent position in the field of therapeutic advancements for autoimmune diseases. Committed to providing a comprehensive and integrated solution, we strive to lead the way in addressing the complexities of AIP.
Overview of Autoimmune Pancreatitis
Autoimmune pancreatitis is a form of chronic pancreatitis that arises from an autoimmune response against pancreatic tissue. It is classified into two distinct types: type 1 (AIP-1) and type 2 (AIP-2). AIP-1 is characterized by elevated serum IgG4 levels and systemic involvement, while AIP-2 is not associated with IgG4 elevation and often presents with concurrent inflammatory bowel disease. AIP-1 is often associated with the presence of IgG4-positive plasma cells and T cells infiltrating pancreatic tissue. These cells produce pro-inflammatory cytokines and chemokines, leading to chronic inflammation and fibrosis. Additionally, aberrant immune responses targeting pancreatic antigens, such as pancreatic secretory trypsin inhibitor (PSTI), have been implicated in AIP pathogenesis.
Fig.1 Autoimmune pancreatitis and intestinal dysbiosis. (Yoshikawa T., et al. 2021)
Drug Discovery and Development for Autoimmune Pancreatitis
The therapeutics of AIP require a multidisciplinary approach, involving both pharmacological interventions and supportive care. Rituximab, a monoclonal antibody targeting CD20, has shown promise as an effective therapy for AIP-1 cases who are resistant to GC or have not responded to immunomodulatory therapies. In addition to rituximab, other targeted therapies are being explored for the therapeutic of AIP. Monoclonal antibodies targeting molecules such as type 1 interferon receptor, CD19, CD38, LOXL2, and SLAMF7 are under investigation for their potential efficacy in AIP and related autoimmune diseases. These targeted therapies hold great promise in providing more precise and effective therapeutics for AIP.
As a dedicated company focused on advancing therapy for AIP, we proudly provide an extensive array of services for therapeutic development. Our comprehensive platform encompasses various facets of therapy research and innovation. To explore further details about our offerings, kindly follow the link provided below.
Our Services
Within our organization, we specialize in the provision of personalized diagnostics and therapeutic development solutions. Our focus lies in delivering cutting-edge services tailored specifically to address the challenges posed by AIP. Through the utilization of state-of-the-art technologies and methodologies, our team of experts excels in the development of diagnostic assays. These assays are meticulously designed to detect and identify specific biomarkers closely linked to AIP.
CD4+ T Cell Adoptive Transfer Models
One of the key approaches we employ is the adoptive transfer of CD4+ T cells specific to pancreatic antigens. By transferring activated CD4+ T cells into naïve recipient mice, we can induce pancreatitis and observe the progression of the disease. The severity of pancreatitis in the mice is directly proportional to the number of transferred T cells.
IgG4-RD Models
The development of an IgG4-related disease (IgG4-RD) model for autoimmune pancreatitis in MRL/Mp mice treated with poly (I:C) offers a valuable tool for studying the immuno-pathogenesis of IgG4-related AIP. Our company's expertise in IgG4-RD model development services ensures that researchers have access to reliable and reproducible models for their studies.
Cell-Based Models
We utilize primary cell cultures derived from pancreatic tissue samples to establish cell-based models for autoimmune pancreatitis. These cultures contain a heterogeneous population of cells, including pancreatic acinar cells, ductal cells, and immune cells, enabling the study of cell-cell interactions and the immune response in the context of AIP.
Organoid Models
Organoids, three-dimensional structures derived from stem cells, provide a powerful tool for studying the complex tissue architecture and cellular interactions in autoimmune pancreatitis. We generate pancreatic organoids from patient-derived cells or stem cells, which can differentiate into various pancreatic cell types.
Why Choose Us?
Equipped with advanced infrastructure and employing state-of-the-art technologies, our facilities empower us to undertake a wide range of in vitro and in vivo studies. These encompass comprehensive investigations into pharmacokinetics, toxicology assessments, and other essential aspects of therapeutic development. In addition to the aforementioned services and models, we also provide customized solutions and develop disease models that cater specifically to your unique needs. If our services have piqued your interest, please do not hesitate to contact us.
References
- Yoshikawa T., et al. "Intestinal dysbiosis and autoimmune pancreatitis." Frontiers in immunology 12 (2021): 621532.
- Nista E. C., et al. "Autoimmune pancreatitis: from pathogenesis to treatment." International journal of molecular sciences 23.20 (2022): 12667.